Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, has announced its participation in two upcoming investor conferences. Rachel Haurwitz, PhD, the company's president and CEO, will join a panel on cell therapies in autoimmune disorders at Citi's 2024 Global Healthcare Conference in Miami on December 3 at 2:30 PM EST. She will also participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference in Coral Gables on December 4 at 10:25 AM EST. Webcasts of both events will be available on Caribou's website for 30 days following the presentations.
Caribou Biosciences (Nasdaq: CRBU), un'azienda biofarmaceutica in fase clinica specializzata nell'editing genomico CRISPR, ha annunciato la sua partecipazione a due prossimi convegni per investitori. Rachel Haurwitz, PhD, presidente e CEO dell'azienda, parteciperà a un panel sulle terapie cellulari nei disturbi autoimmuni alla 2024 Global Healthcare Conference di Citi a Miami il 3 dicembre alle 14:30 EST. Parteciperà anche a una conversazione informale alla 7th Annual Evercore ISI HealthCONx Conference a Coral Gables il 4 dicembre alle 10:25 EST. Le registrazioni di entrambi gli eventi saranno disponibili sul sito web di Caribou per 30 giorni dopo le presentazioni.
Caribou Biosciences (Nasdaq: CRBU), una empresa biofarmacéutica en etapa clínica especializada en edición de genomas CRISPR, ha anunciado su participación en dos próximas conferencias para inversores. Rachel Haurwitz, PhD, presidenta y CEO de la empresa, se unirá a un panel sobre terapias celulares en trastornos autoinmunes en la 2024 Global Healthcare Conference de Citi en Miami el 3 de diciembre a las 2:30 PM EST. También participará en una charla al calor de la conversación en la 7th Annual Evercore ISI HealthCONx Conference en Coral Gables el 4 de diciembre a las 10:25 AM EST. Las retransmisiones de ambos eventos estarán disponibles en el sitio web de Caribou durante 30 días después de las presentaciones.
Caribou Biosciences (Nasdaq: CRBU)는 임상 단계에 있는 CRISPR 유전자 편집 바이오 제약 회사로, 두 개의 다가오는 투자자 회의에 참여할 것이라고 발표했습니다. Rachel Haurwitz, PhD는 12월 3일 EST 오후 2:30에 마이애미에서 열리는 Citi의 2024 Global Healthcare Conference에서 자가면역 질환의 세포 치료에 관한 패널에 참여할 예정입니다. 또한, 12월 4일 EST 오전 10:25에 코랄 게이블스에서 열리는 7th Annual Evercore ISI HealthCONx Conference에서 화기애애한 대화에 참여할 것입니다. 두 이벤트의 웹캐스트는 발표 후 30일 동안 Caribou 웹사이트에서 이용 가능할 것입니다.
Caribou Biosciences (Nasdaq: CRBU), une entreprise biopharmaceutique en phase clinique spécialisée dans l'édition génique par CRISPR, a annoncé sa participation à deux prochaines conférences pour investisseurs. Rachel Haurwitz, PhD, présidente et PDG de l'entreprise, participera à un panel sur les thérapies cellulaires dans les troubles auto-immuns lors de la 2024 Global Healthcare Conference de Citi à Miami, le 3 décembre à 14h30 EST. Elle participera également à une discussion informelle lors de la 7th Annual Evercore ISI HealthCONx Conference à Coral Gables, le 4 décembre à 10h25 EST. Les webinaires des deux événements seront disponibles sur le site de Caribou pendant 30 jours après les présentations.
Caribou Biosciences (Nasdaq: CRBU), ein biopharmazeutisches Unternehmen in der klinischen Phase, das auf CRISPR-Genomeditierung spezialisiert ist, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Rachel Haurwitz, PhD, die Präsidentin und CEO des Unternehmens, wird an einem Panel über Zelltherapien bei Autoimmunerkrankungen auf der 2024 Global Healthcare Conference von Citi in Miami am 3. Dezember um 14:30 Uhr EST teilnehmen. Außerdem wird sie an einem informellen Gespräch auf der 7th Annual Evercore ISI HealthCONx Conference in Coral Gables am 4. Dezember um 10:25 Uhr EST teilnehmen. Die Webcasts beider Veranstaltungen sind 30 Tage nach den Präsentationen auf der Website von Caribou verfügbar.
- None.
- None.
BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in the following investor conferences:
- Citi's 2024 Global Healthcare Conference, Miami, FL
December 3, 2024, panel at 2:30 PM EST
Panel title: Cell therapies in autoimmune disorders
Webcast
- 7th Annual Evercore ISI HealthCONx Conference, Coral Gables, FL
December 4, 2024, fireside chat at 10:25 AM EST
Webcast
For more information, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the event.
About Caribou’s novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com
Media:
Peggy Vorwald, PhD
media@cariboubio.com
FAQ
When is Caribou Biosciences (CRBU) presenting at Citi's 2024 Global Healthcare Conference?
What is the topic of Caribou Biosciences' (CRBU) panel at the Citi Healthcare Conference 2024?
When can investors watch the webcasts of Caribou Biosciences' (CRBU) December 2024 conference presentations?
Which investor conferences is Caribou Biosciences (CRBU) attending in December 2024?
